1 / 14

UCB Group Preliminary Results 2002 Conference Call

UCB Group Preliminary Results 2002 Conference Call. Georges Jacobs Chief Executive Officer, UCB Group Marc Wiers Chief Financial Officer, UCB Group Luc Debeer Scientific Advisor, Pharma Sector UCB Group Arnaud Denis Investor Relations Officer, UCB Group. 6 February 2003

evania
Download Presentation

UCB Group Preliminary Results 2002 Conference Call

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. UCB Group Preliminary Results 2002 Conference Call Georges Jacobs Chief Executive Officer, UCB Group Marc Wiers Chief Financial Officer, UCB Group Luc Debeer Scientific Advisor, Pharma Sector UCB Group Arnaud Denis Investor Relations Officer, UCB Group 6 February 2003 18h00 Central European Time

  2. Turnover: EUR 2,514 millions UCB Group Turnover in EUR million Ordinary profit margin

  3. Sectorial Breakdown UCB Group 2001 2002 (in EUR million) Pharma 1,427 1,476 Surface Specialties 1,048 1,037 Chemicals 652 643 Films 396 394 Non sectorial - 1 Total Turnover 2,475 2,514 +2% Pharma 403 440 Surface Specialties 49 34 Chemicals 40 47 Films 9 -13 Non sectorial 10 20 Total Ordinary Profit 462 494 +7% Exceptional -6 -28 Taxation -136 -136 Net Income 318 331 +4%

  4. Pharma UCB Pharma (in EUR million) 2001 2002 • Allergy/Asthma • Zyrtec • Xyzal Turnover 1,427 1,476 Ordinary profit 403 440 Ordinary Margin28%30% • Neurology • Keppra • Nootropil • Atarax • Others • Peptides • Lortab (USA) • Stogar Japan) 23% 28% Others Neurology 49% Allergy

  5. Allergy Franchise Global In-Market Sales: EUR 1.7 billion Pharma (in EUR million) • USA: Zyrtec only antihistamine approved for safety and efficacy in infants as young as 6 months • EUROPE: Xyzal continuing roll-out in Europe with new clinical data • JAPAN: Imposed price cut of 6% 2001 2002 (in local currency) USA 1,104 1,184 +13% Europe 354 315 -11% Japan 163 141 - 6% R. of W. 51 58 +12% Total incl. licencees 1,672 1,698 +2% Pfizer royalties 137 151 +16%

  6. Keppra Sales : EUR 231 millions Pharma • Third best selling productin the new AED market in epilepsy indication • Critical 200,000 patient-yearsmilestone surpassed • Most succesful launch in key markets vs. existing new AEDs (in EUR million) 2001 2002 (in local currency) USA 96 164 +79% Europe 26 66 +156% R. of W. 0 1 Totalrevenue 122 231 +89%

  7. Increasingly Healthy Product Mix Pharma Turnover in EUR million 16% 49% 9% 3% 23%

  8. UCB Chemicals (former structure) Surface Specialties • Radcure resins curable by ultraviolet and electron beam • Crylcoat polyester resins for electrostatic powder coatings • Acrylic resins and polyurethanes • Methylamines and derivatives (in EUR million) 2001 2002 Turnover 652 643 Ordinary profit 40 47 Ordinary Margin6% 7% 9% Polyur. 28% 41% Methylamines Radcure 22% Crylcoat

  9. UCB Films (former structure) Surface Specialties • OPP Films • - Films for Labels • - Overwrapping • - Coated films • - Security films • Cellulose Films • - Specialty Packaging • - Industrial Uses (in EUR million) 2001 2002 Turnover 396 394 Ordinary profit 9 - 13 Ordinary Margin 2% -3% 44% 56% Cellophane OPP

  10. New Structure (pro-forma at 2002 year-end) Surface Specialties (in EUR million) 2001 2002 • Reaching critical mass • Highly complementary product offering with • unmatched application • and solution portfolio • Strong position to achieve global leadership • Synergies to realise • improvement in profitability Turnover 1,686 1,659 Chemicals 652 643 Films 396 394 Solutia RA&A 638 622 Surface Specialties: - 4,700 Employees - 25 sites (Production & R&D)

  11. 2002: Continued Growth despite pressured environment UCB Group Highlights: • Keppra: close to doubling its sales, 200,000 patient-years surpassed • Allergy Franchise: worldwide sales growth despite pressures • Surface Specialties: largest acquisition of UCB Chemicals: increase profit contribution Films: - restructuring efforts - recovery targeted for end-2003

  12. Outlook and Challenges for 2003 UCB Group • Pharma • Consolidate our position as a world leader in the anti-allergic field • Further develop the success of Keppra • Continuing increase in R&D effort • Surface Specialties • Integrate and launch the new structure • Reap first benefits of synergies • Continue to profit from improvement plan of the Films activities

More Related